Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2666)	7/28/2011 1:14:54 PM
From: software salesperson	2 Recommendations Read Replies (1) \| Respond to of 3202

7/28/11 cc notes 1. Opening remarks Rux NDA submitted 6/3; has verbally confirmed that it has been granted priority review and PDUFA date is 12/3 NVS submitted rux MAA in june Finalizing distribution network and patient assistance program Response advanced PV trial behind schedule - - in dialogue with FDA; study protocol to be amended to accelerate enrollment; proposed keeping dual endpoints of phlebotomy independence and spleen size reduction; reduce study size; relax entry criteria Other rux trials, especially P2 pancreatic study that was initiated this month 050 P2b is on track and 3 month placebo controlled phase of trial expected to complete in early ‘12 Sheddase 7839 - - still analyzing IDO and cMet inhibitors continue in P1; haven’t reached MTD for either compound; future IDO trial 1st ½ ’12 in metastatic melanoma or advanced ovarian Cash 6/30/11 - - 364 M 2. q & a ( i) revised PV study because of lower market opportunity or overly stringent enrollment criteria? - - latter; if amended, will go back to recruit same patients; high screen failure rate; relatively easy fix (ii) how long to gain agreement to amend study? - - have to revise SPA; doesn’t see it dragging on; if agreed to quickly, will not change guidance for when study will be completed (iii) why are people failing screening process? - - one example - - patients are phlebotomy dependent and have big spleens; criteria say that have to have either or both elevated white blood cell counts or elevated platelet counts; but many patients don’t meet all these criteria (iv) how did this criteria screwup happen? - - no direct answer (v) have to go thru new SPA process? - - it’s an amendment to a protocol - - perhaps 45 days (vi) label indication would be the same? - - new potential label will increase patient population (vii) re: rux NDA, will there be an advisory panel? - - haven’t been notified, but preparing for one (viii) how soon after approval would you launch rux? - - 10 days (ix) any guidance from NVS re: rux advisory panel? - - none to date (x) any guidance from NVS re: rux launch? - - we handle US and we talk to them re: common interests (xi) 050 3 month data? - - it will be up to LLY as to when to release, PR or medical meeting (xii) re: PV, still optimistic that can be done under SPA? - - yes (xiii) re: sheddase, commercial analysis now part of decision? - - 2 new treatments have emerged; wants to see if market still there (xiv) ASCO transfusion independence criteria, any progress on standard guidelines? - - new guidelines would make sense (xv) post approval requirements for rux? - - durability, probably not survival-related (xvi) rux payor mix? - - medicare 40%; self-pay 12%; Medicaid 5%; commercial pay 43% (xvii) what will rux price be? - - no direct answer; probably ~ 60 k; could be higher (xviii) are all PV sites recruiting now? - - they are waiting on revised criteria; the sites are OK (xix) comparable products to rux? - - gleevec, tasigna, sprycel, sutent, etc. (xx) anticipated uptake of rux? - - slow and steady (xxi) what % of potential rux US patients are severe, moderate, mild ? - - 1/3 each (xxii) PV screen failures, thinking of getting rid of intolerant of HU? - - that would help some, but the white blood cell/platelet count is bigger issue (xxiii) P2 PV data, 2/3 of patients titrated dose lower than 10 mg BID. Same expectation for P3? What’s the impact on pricing vis-à-vis MF pricing? - - 10 mg BID will be starting dose; titration will still occur; flat pricing regardless of strength (xxiv) communicated with CMS yet? - - more important for infused products, not oral ones (xxv) rux P2 pancreatic pre-clinical activity? - - in mice (xxvi) P1 / 2 rux data for other hematological cancers? - - ASH ‘12 (xxvii) share count? - - 190 M 3. impressions sounded like the rux NDA and launch are in good shape; we’ll see how easily it will be to recover from PV screwup; surprised that, after ASCO, no one called him re: his bombastic statement : “I will guarantee you that there is no difference( in transfusion independence between us and Cytopia)” sales